Skip to main content

Table 1 Patient demographic, baseline disease, and treatment characteristics

From: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Characteristic EVE+EXE (n = 485), % PBO+EXE (n = 239), %
Median age, years (range) 62 (34–93) 61 (28–90)
Race
 White 74 78
 Asian 20 19
 Black 3 1
 Other 3 2
ECOG performance status 0 60 59
Visceral disease 58 59
Measurable diseasea 70 68
Metastatic site
 Lung 30 33
 Liver 33 30
 Bone 77 77
Prior therapy
 Setting of most recent treatment
  Adjuvant 21 16
  Advanced/metastatic disease 79 84
 LET or ANA as most recent treatment 74 75
 Tamoxifen 47 50
 Fulvestrant 17 16
 Chemotherapy (any setting) 69 65
 Chemotherapy for metastatic BC 26 26
 Radiotherapy 70 69
 Number of prior therapiesb
  1 or 2 46 47
  ≥3 54 53
  1. From Baselga et al. [16]. Copyright © 2012 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Any minor differences between this table and the original report by Baselga et al. [16] are a consequence of the investigator’s data correction at the subsequent analysis
  2. ANA anastrozole, BC breast cancer, ECOG Eastern Cooperative Oncology Group, EVE everolimus, EXE exemestane, LET letrozole, PBO placebo
  3. aAll other patients had ≥1 mainly lytic bone lesion
  4. bPrior therapies include those used in the adjuvant setting or to treat advanced disease